Quotazioni in diretta

REGN Regeneron Pharmaceuticals Inc

985,02

4,45 (0,45%)

25 Mag 2024 - Chiuso

Dati in Delay di 15 minuti

Biotech Shares Soar Premarket On Sale Of R&D Assets

A Massachusetts-based biotech company is stealing the show so far during Tuesday’s premarket hours after it was announced that the company has agreed to sell its pipeline of...

To read the full story on AllPennyStocks.com, click here.

Grafico Azioni Regeneron Pharmaceuticals (NASDAQ:REGN)
Storico
Da Apr 2024 a Mag 2024

Clicca qui per i Grafici di Regeneron Pharmaceuticals

Grafico Azioni Regeneron Pharmaceuticals (NASDAQ:REGN)
Storico
Da Mag 2023 a Mag 2024

Clicca qui per i Grafici di Regeneron Pharmaceuticals

Notizie Regeneron Pharmaceuticals Inc - REGN

Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
Giovedì 23 Maggio 2024 (2 giorni fa) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Mercoledì 22 Maggio 2024 (3 giorni fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Martedì 21 Maggio 2024 (4 giorni fa) • Edgar (US Regulatory)

Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
Lunedì 20 Maggio 2024 (5 giorni fa) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Venerdì 17 Maggio 2024 (1 settimana fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Venerdì 17 Maggio 2024 (1 settimana fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Venerdì 17 Maggio 2024 (1 settimana fa) • Edgar (US Regulatory)

More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
Venerdì 17 Maggio 2024 (1 settimana fa) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Giovedì 16 Maggio 2024 (1 settimana fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Martedì 14 Maggio 2024 (2 settimane fa) • Edgar (US Regulatory)

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
Lunedì 13 Maggio 2024 (2 settimane fa) • GlobeNewswire Inc.

Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
Mercoledì 8 Maggio 2024 (2 settimane fa) • GlobeNewswire Inc.

Più Regeneron Pharmaceuticals Inc Articoli Notizie

Intesa Sanpaolo

ST Microelectronics

Banca Monte Dei Paschi D...

Delayed Upgrade Clock

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea